GSK’s Depemokimab Shows Promising Results in Phase 3 Trials, Reducing Asthma Attacks by Half

Depemokimab Success:
GSK's long-acting asthma drug, Depemokimab, has successfully met its primary endpoints in two Phase 3 trials (SWIFT-1 and SWIFT-2), significantly reducing asthma attacks over 52 weeks compared to a placebo.

Dosing Schedule:
Depemokimab is administered every six months, offering a more convenient treatment option for patients with severe asthma compared to existing biologics like Nucala, which is given every four weeks.

Target Population:
The trials focused on adults and adolescents with severe asthma characterized by Type 2 inflammation and elevated blood eosinophil counts.

Regulatory Plans:
GSK plans to seek regulatory approval for Depemokimab in the US in the latter half of 2024 and in the EU, China, and Japan in 2025.

Market Potential:
Depemokimab is expected to generate significant sales, with GSK forecasting peak year sales of approximately $3.9 billion, surpassing Nucala's $2.1 billion in 2023.

Clinical Significance:
The success of Depemokimab in reducing asthma attacks supports its potential as a blockbuster drug, offering a new treatment option for patients with severe asthma who may benefit from a longer-acting biologic therapy.